Therapy Areas: Allergy
ALK Abello announces securing of pricing by its Japanese partner for new Japanese cedar SLIT-tablet
19 April 2018 - ALK-Abelló A/S (ALK) (CPH:ALKB), a Danish, specialty pharmaceutical company focused on allergy and allergic asthma, announced on Wednesday that its partner for Japan, Torii Phar...
ALK -Abello partners with Rellergen in China to gain rights to market Bio-IC technology
12 April 2018 - ALK-Abello A/S (CPH:ALKB), a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, on Wednesday announced a partnership with China'...
Dr. Reddy's Laboratories Launches Levocetirizine Dihydrochloride Tablets USP, 5 mg in the US
20 March 2018 - - Hyderabad, India-based integrated pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched Levocetirizine Dihydrochloride Tablet...
Aevi Genomic Medicine and Kyowa Hakko Kirin Partner to Develop Monoclonal Antibody Programme in Ultra-orphan Pediatric Indication
12 March 2018 - - Wayne, Pennsylvania-based pediatric-onset disease therapeutics developer Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) has expanded its collaboration with Japan-based life sciences comp...
MicuRx awarded CARB-X's grant for innovative polymyxin antibiotic MRX-8
6 March 2018 - Biopharmaceutical company MicuRx Pharmaceuticals Inc said on Monday that it expects up to USD5.2m of non-dilutive financing for IND enablement and subsequent Phase 1 clinical studies of...
New global chronic urticaria guideline recommends Novartis' Xolair
6 March 2018 - A new global guideline on chronic urticaria (UC) has recommended Novartis' (VTX: NOVN) Xolair (omalizumab) as an add-on therapy for the treatment of chronic spontaneous urticaria (...